Data intelligence · automation · analyticsA Praxis Global Institute platform
Praxis Data Lab

Praxis Data Lab · Variable History

Variable history and harmonization report.

Review variable definitions, cycle chronology, survey design, laboratory methods, method-change boundaries, detection limits, and evidence-backed harmonization actions.

50matching variable codes

115 release records across 13 datasets and 8 cycles.

Back to Explorer

Search scope

Results for “ELISA”

Harmonization summary

45 label-stable codes

Label changes detected
0
Multiple dataset contexts
5
Unique codes
50
Enriched codes in this report
0

Scientific safeguard

Qualified assessment is authoritative; chronology remains supporting evidence.

Praxis separates source-stated method or instrument changes from automated differences in CDC/NCHS method text. The qualified harmonization assessment below is the researcher-facing conclusion; method chronology explains the underlying evidence and does not override that adjudication.

Variable-by-variable chronology

Qualified harmonization assessment and indexed evidence

Each variable first shows the current qualified assessment used by Study Builder, followed by cycle-specific source evidence and method chronology.

ELISAEvidence developing

ELISA result interpretation

Observed years
2003–2004
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • ELISA result interpretation — 2003-2004
Cycle-by-cycle release history
  • 2003-2004: SSQFEV_C — ELISA result interpretation — Coxiella Burnetii (Q Fever) Antibodies - Serum (Surplus) (Laboratory)
LBD911LCCompatible with harmonization

HPV 11 (Quantitative) comment code

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 11 (Quantitative) comment code — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 11 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV 11 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 11 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD916LCCompatible with harmonization

HPV 16 (Quantitative) comment code

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 16 (Quantitative) comment code — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 16 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV 16 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 16 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD918LCCompatible with harmonization

HPV 18 (Quantitative) comment code

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 18 (Quantitative) comment code — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 18 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV 18 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 18 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD931LCCompatible with harmonization

HPV 31 (Quantitative) comment code

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 31 (Quantitative) comment code — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 31 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV 31 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 31 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD933LCCompatible with harmonization

HPV 33 (Quantitative) comment code

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 33 (Quantitative) comment code — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 33 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV 33 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 33 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD945LCCompatible with harmonization

HPV 45 (Quantitative) comment code

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 45 (Quantitative) comment code — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 45 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV 45 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 45 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD952LCCompatible with harmonization

HPV 52 (Quantitative) comment code

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 52 (Quantitative) comment code — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 52 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV 52 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 52 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD958LCCompatible with harmonization

HPV 58 (Quantitative) comment code

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 58 (Quantitative) comment code — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 58 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV 58 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 58 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD96NLCCompatible with harmonization

HPV 6 (Quantitative) comment code

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 6 (Quantitative) comment code — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 6 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV 6 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 6 (Quantitative) comment code — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD9M11NCompatible with harmonization

HPV 11 (IU/mL)

Observed years
2013–2016
Release records
2
Datasets
2
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 11 (IU/mL) — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: HPVN_H_R — HPV 11 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 11 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD9M16NCompatible with harmonization

HPV 16 (IU/mL)

Observed years
2013–2016
Release records
2
Datasets
2
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 16 (IU/mL) — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: HPVN_H_R — HPV 16 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 16 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD9M18NCompatible with harmonization

HPV 18 (IU/mL)

Observed years
2013–2016
Release records
2
Datasets
2
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 18 (IU/mL) — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: HPVN_H_R — HPV 18 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 18 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD9M31NCompatible with harmonization

HPV 31 (IU/mL)

Observed years
2013–2016
Release records
2
Datasets
2
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 31 (IU/mL) — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: HPVN_H_R — HPV 31 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 31 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD9M33NCompatible with harmonization

HPV 33 (IU/mL)

Observed years
2013–2016
Release records
2
Datasets
2
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 33 (IU/mL) — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: HPVN_H_R — HPV 33 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 33 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD9M45NCompatible with harmonization

HPV 45 (IU/mL)

Observed years
2013–2016
Release records
2
Datasets
2
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 45 (IU/mL) — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: HPVN_H_R — HPV 45 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 45 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD9M52NCompatible with harmonization

HPV 52 (IU/mL)

Observed years
2013–2016
Release records
2
Datasets
2
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 52 (IU/mL) — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: HPVN_H_R — HPV 52 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 52 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD9M58NCompatible with harmonization

HPV 58 (IU/mL)

Observed years
2013–2016
Release records
2
Datasets
2
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 58 (IU/mL) — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: HPVN_H_R — HPV 58 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 58 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBD9M6NCompatible with harmonization

HPV 6 (IU/mL)

Observed years
2013–2016
Release records
2
Datasets
2
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV 6 (IU/mL) — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: HPVN_H_R — HPV 6 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV 6 (IU/mL) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M11Compatible with harmonization

HPV11 9-plex coded result

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV11 9-plex coded result — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV11 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV11 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV11 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M11NEvidence developing

HPV 11 (Quantitative)

Observed years
2005–2006
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • HPV 11 (Quantitative) — 2005-2006
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 11 (Quantitative) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M16Compatible with harmonization

HPV16 9-plex coded result

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV16 9-plex coded result — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV16 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV16 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV16 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M16NEvidence developing

HPV 16 (Quantitative)

Observed years
2005–2006
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • HPV 16 (Quantitative) — 2005-2006
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 16 (Quantitative) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M18Compatible with harmonization

HPV18 9-plex coded result

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV18 9-plex coded result — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV18 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV18 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV18 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M18NEvidence developing

HPV 18 (Quantitative)

Observed years
2005–2006
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • HPV 18 (Quantitative) — 2005-2006
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 18 (Quantitative) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M31Compatible with harmonization

HPV31 9-plex coded result

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV31 9-plex coded result — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV31 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV31 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV31 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M31NEvidence developing

HPV 31 (Quantitative)

Observed years
2005–2006
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • HPV 31 (Quantitative) — 2005-2006
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 31 (Quantitative) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M33Compatible with harmonization

HPV33 9-plex coded result

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV33 9-plex coded result — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV33 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV33 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV33 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M33NEvidence developing

HPV 33 (Quantitative)

Observed years
2005–2006
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • HPV 33 (Quantitative) — 2005-2006
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 33 (Quantitative) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M45Compatible with harmonization

HPV45 9-plex coded result

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV45 9-plex coded result — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV45 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV45 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV45 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M45NEvidence developing

HPV 45 (Quantitative)

Observed years
2005–2006
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • HPV 45 (Quantitative) — 2005-2006
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 45 (Quantitative) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M52Compatible with harmonization

HPV52 9-plex coded result

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV52 9-plex coded result — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV52 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV52 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV52 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M52NEvidence developing

HPV 52 (Quantitative)

Observed years
2005–2006
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • HPV 52 (Quantitative) — 2005-2006
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 52 (Quantitative) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M58Compatible with harmonization

HPV58 9-plex coded result

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV58 9-plex coded result — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV58 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV58 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV58 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M58NEvidence developing

HPV 58 (Quantitative)

Observed years
2005–2006
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • HPV 58 (Quantitative) — 2005-2006
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 58 (Quantitative) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M6Compatible with harmonization

HPV6 9-plex coded result

Observed years
2005–2016
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 2005-2006 → 2013-2014 · 2013-2014 → 2015-2016

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • HPV6 9-plex coded result — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV6 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — HPV6 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — HPV6 9-plex coded result — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
LBX9M6NEvidence developing

HPV 6 (Quantitative)

Observed years
2005–2006
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • HPV 6 (Quantitative) — 2005-2006
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — HPV 6 (Quantitative) — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
SEQNAdjustment required

Respondent sequence number.

Observed years
2005–2016
Release records
7
Datasets
7
Components
Laboratory
Qualified Praxis harmonization assessment

Adjustment required · high confidence

A methodological discontinuity falls inside the selected cycle span. Naive pooling of raw values across the flagged boundary is not recommended unless CDC/NCHS provides a defensible calibration or comparability procedure.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 1999-2000 → 2001-2002 · 2001-2002 → 2003-2004 · 2003-2004 → 2005-2006 · 2005-2006 → 2007-2008 · 2007-2008 → 2009-2010 · 2009-2010 → 2011-2012 · 2011-2012 → 2013-2014 · 2013-2014 → 2015-2016 · 2015-2016 → 2017-2018 · 2017-2018 → 2017-2020 · 2017-2020 → 2021-2023

Praxis harmonization actions
  • Apply cycle-specific eligibility rules and restrict the pooled analytic population to a defensible common target population.
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Review the adjacent codebooks/methods. Keep this boundary as documentation variation unless source evidence confirms a substantive method or instrument change.
  • Select the weight appropriate to each cycle and subsample; when pooling cycles, construct the combined weight according to NHANES guidance rather than reusing a single-cycle weight unchanged.
  • Apply CDC/NCHS comparability or calibration guidance where available. If equivalence is not established, preserve separate method periods or perform sensitivity analyses rather than naively pooling raw values.
  • Confirm that the construct and coding are unchanged before pooling or recoding.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • Respondent sequence number. — 2005-2006 · 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2005-2006: HPVN_D_R — Respondent sequence number. — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody - Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: HPVN_H_R — Respondent sequence number. — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2013-2014: SSCT_H — Respondent sequence number. — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results (Laboratory)
  • 2013-2014: SSCT_H_R — Respondent sequence number. — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results - Youth (Laboratory) — Note: RDC Only
  • 2015-2016: HPVN_I_R — Respondent sequence number. — Human Papillomavirus (HPV) - 6, 11, 16, 18, 31, 33, 45, 52, & 58 Antibody – Serum: M9ELISA (Laboratory) — Note: RDC Only
  • 2015-2016: SSCT_I — Respondent sequence number. — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results (Laboratory)
  • 2015-2016: SSCT_I_R — Respondent sequence number. — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results - Youth (Laboratory) — Note: RDC Only
SSCMVODCompatible with harmonization

CMV optical density from ELISA

Observed years
1999–2004
Release records
3
Datasets
3
Components
Laboratory
Qualified Praxis harmonization assessment

Compatible with harmonization · moderate confidence

No blocking method discontinuity is identified inside the selected cycle span, but one or more longitudinal changes require explicit harmonization conditions before pooling.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Relevant boundaries: 1999-2000 → 2001-2002 · 2001-2002 → 2003-2004

Praxis harmonization actions
  • Verify merge grain, companion variables, and component-specific analytic guidance for the new file context.
  • Select the weight appropriate to each cycle and subsample; when pooling cycles, construct the combined weight according to NHANES guidance rather than reusing a single-cycle weight unchanged.
Supporting CDC/NCHS evidence
Variable names / labels over time
  • CMV optical density from ELISA — 1999-2000 · 2001-2002 · 2003-2004
Cycle-by-cycle release history
  • 1999-2000: SSCMV_A — CMV optical density from ELISA — Cytomegalovirus Antibodies - Serum (Surplus) (Laboratory)
  • 2001-2002: SSCMV_B — CMV optical density from ELISA — Cytomegalovirus Antibodies - Serum (Surplus) (Laboratory)
  • 2003-2004: SSCMV_C — CMV optical density from ELISA — Cytomegalovirus Antibodies - Serum (Surplus) (Laboratory)
SSCTEIAEvidence developing

Chlamydia Pgp3 ELISA

Observed years
2013–2016
Release records
4
Datasets
4
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Chlamydia Pgp3 ELISA — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: SSCT_H — Chlamydia Pgp3 ELISA — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results (Laboratory)
  • 2013-2014: SSCT_H_R — Chlamydia Pgp3 ELISA — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results - Youth (Laboratory) — Note: RDC Only
  • 2015-2016: SSCT_I — Chlamydia Pgp3 ELISA — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results (Laboratory)
  • 2015-2016: SSCT_I_R — Chlamydia Pgp3 ELISA — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results - Youth (Laboratory) — Note: RDC Only
SSCTEIODEvidence developing

Chlamydia Pgp3 EIA Optical Density

Observed years
2013–2016
Release records
4
Datasets
4
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Chlamydia Pgp3 EIA Optical Density — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: SSCT_H — Chlamydia Pgp3 EIA Optical Density — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results (Laboratory)
  • 2013-2014: SSCT_H_R — Chlamydia Pgp3 EIA Optical Density — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results - Youth (Laboratory) — Note: RDC Only
  • 2015-2016: SSCT_I — Chlamydia Pgp3 EIA Optical Density — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results (Laboratory)
  • 2015-2016: SSCT_I_R — Chlamydia Pgp3 EIA Optical Density — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results - Youth (Laboratory) — Note: RDC Only
SSCTIGEvidence developing

Detection of anti-C. trachomatis (CT) pan-IgG (IgG1, IgG2, IgG3, IgG4) by mixed peptide ELISA

Observed years
2017–2018
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Detection of anti-C. trachomatis (CT) pan-IgG (IgG1, IgG2, IgG3, IgG4) by mixed peptide ELISA — 2017-2018
Cycle-by-cycle release history
  • 2017-2018: SSCH_J_R — Detection of anti-C. trachomatis (CT) pan-IgG (IgG1, IgG2, IgG3, IgG4) by mixed peptide ELISA — Chlamydia Serology - Serum (Surplus) (Laboratory) — Note: RDC Only
SSCTIG1Evidence developing

Detection of anti-C. trachomatis (CT) IgG1 by mixed peptide ELISA

Observed years
2017–2018
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Detection of anti-C. trachomatis (CT) IgG1 by mixed peptide ELISA — 2017-2018
Cycle-by-cycle release history
  • 2017-2018: SSCH_J_R — Detection of anti-C. trachomatis (CT) IgG1 by mixed peptide ELISA — Chlamydia Serology - Serum (Surplus) (Laboratory) — Note: RDC Only
SSCTIG1OEvidence developing

Optical density (OD) 450 nm values for anti-C. trachomatis (CT) IgG1 on mixed peptide ELISA

Observed years
2017–2018
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Optical density (OD) 450 nm values for anti-C. trachomatis (CT) IgG1 on mixed peptide ELISA — 2017-2018
Cycle-by-cycle release history
  • 2017-2018: SSCH_J_R — Optical density (OD) 450 nm values for anti-C. trachomatis (CT) IgG1 on mixed peptide ELISA — Chlamydia Serology - Serum (Surplus) (Laboratory) — Note: RDC Only
SSCTIG3Evidence developing

Detection of anti-C. trachomatis (CT) IgG3 by mixed peptide ELISA

Observed years
2017–2018
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Detection of anti-C. trachomatis (CT) IgG3 by mixed peptide ELISA — 2017-2018
Cycle-by-cycle release history
  • 2017-2018: SSCH_J_R — Detection of anti-C. trachomatis (CT) IgG3 by mixed peptide ELISA — Chlamydia Serology - Serum (Surplus) (Laboratory) — Note: RDC Only
SSCTIG3OEvidence developing

Optical density (OD) 450 nm values for anti-C. trachomatis (CT) IgG3 on mixed peptide ELISA

Observed years
2017–2018
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Optical density (OD) 450 nm values for anti-C. trachomatis (CT) IgG3 on mixed peptide ELISA — 2017-2018
Cycle-by-cycle release history
  • 2017-2018: SSCH_J_R — Optical density (OD) 450 nm values for anti-C. trachomatis (CT) IgG3 on mixed peptide ELISA — Chlamydia Serology - Serum (Surplus) (Laboratory) — Note: RDC Only
SSCTIGOEvidence developing

Optical density (OD) 450 nm values for anti-C. trachomatis (CT) pan-IgG (IgG1, IgG2, IgG3, IgG4) on mixed peptide ELISA

Observed years
2017–2018
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Optical density (OD) 450 nm values for anti-C. trachomatis (CT) pan-IgG (IgG1, IgG2, IgG3, IgG4) on mixed peptide ELISA — 2017-2018
Cycle-by-cycle release history
  • 2017-2018: SSCH_J_R — Optical density (OD) 450 nm values for anti-C. trachomatis (CT) pan-IgG (IgG1, IgG2, IgG3, IgG4) on mixed peptide ELISA — Chlamydia Serology - Serum (Surplus) (Laboratory) — Note: RDC Only
SSCTMBAEvidence developing

Chlamydia Pgp3 MBA

Observed years
2013–2016
Release records
4
Datasets
4
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Chlamydia Pgp3 MBA — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: SSCT_H — Chlamydia Pgp3 MBA — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results (Laboratory)
  • 2013-2014: SSCT_H_R — Chlamydia Pgp3 MBA — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results - Youth (Laboratory) — Note: RDC Only
  • 2015-2016: SSCT_I — Chlamydia Pgp3 MBA — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results (Laboratory)
  • 2015-2016: SSCT_I_R — Chlamydia Pgp3 MBA — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results - Youth (Laboratory) — Note: RDC Only
SSCTMBFIEvidence developing

Chlamydia Ppg3 MBA medium fluorescence intensity

Observed years
2013–2016
Release records
4
Datasets
4
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Chlamydia Ppg3 MBA medium fluorescence intensity — 2013-2014 · 2015-2016
Cycle-by-cycle release history
  • 2013-2014: SSCT_H — Chlamydia Ppg3 MBA medium fluorescence intensity — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results (Laboratory)
  • 2013-2014: SSCT_H_R — Chlamydia Ppg3 MBA medium fluorescence intensity — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results - Youth (Laboratory) — Note: RDC Only
  • 2015-2016: SSCT_I — Chlamydia Ppg3 MBA medium fluorescence intensity — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results (Laboratory)
  • 2015-2016: SSCT_I_R — Chlamydia Ppg3 MBA medium fluorescence intensity — Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results - Youth (Laboratory) — Note: RDC Only
SSVARGIEvidence developing

Varicella gpELISA Interpretation

Observed years
2017–2020
Release records
1
Datasets
1
Components
Laboratory
Qualified Praxis harmonization assessment

Evidence developing · low confidence

No normalized longitudinal change evidence is available for this variable. Absence of events must not be interpreted as proof of cross-cycle equivalence.

Evidence provenance: Praxis automated inference from indexed CDC/NCHS evidence

Variable names / labels over time
  • Varicella gpELISA Interpretation — 2017-2020
Cycle-by-cycle release history
  • 2017-2020: P_SSMMRV — Varicella gpELISA Interpretation — Measles, Mumps, Rubella, & Varicella – Serum (Surplus) (Laboratory)